Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Science Park of Barcelona, Barcelona, Spain
Auto-generated profile, based on publicly available information
Inés Martínez-Soria
Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Science Park of Barcelona, Barcelona, Spain
ADGRD1 (GPR133) is an orphan adhesion G protein-coupled receptor (aGPCR) that primarily signals through G s to regulate intracellular cAMP levels and is increasingly recognized for its roles across multiple tissues, including the central nervous system. Its conserved expression in neural tissues, the presence of splice variants in the fetal brain, and its structural similarity to other aGPCRs all suggest that it might play important roles in the organization of neural circuits. Recent studies have identified a wide range of extracellular, membrane- associated, and intracellular interacting partners, highlighting the receptor’s ability to integrate diverse signals. In this study, we explored the consequences of Adgrd1 deficiency in mice using behavioral, electrophysiological, and transcriptomic approaches. Adgrd1-null mice showed reduced nest-building behavior and decreased exploratory drive, while motor coordination and recognition memory remained largely intact. Electrophysiological recordings indicated a trend toward impaired long-term potentiation. These mice also exhibit increased susceptibility to kainate-induced excitotoxicity. RNA-seq analysis revealed coordinated changes in genes associated with inhibitory signaling, extracellular matrix organization, and cytoskeletal regulation, pointing to a shift toward reduced synaptic stabilization and increased hippocampal vulnerability. Altogether, these results suggest that Adgrd1 plays a key role in maintaining hippocampal resilience and regulating motivational behaviors through integrated molecular and circuit-level mechanisms.
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ) peptides, which are a key factor in its pathogenesis. In this study, we present the design and evaluation of γ-amino-L-proline peptides as metabolically stable, cell-penetrating molecules that can modulate amyloidogenic processing. We screened a library of γ-peptides in primary neuronal cultures to determine their effects on endogenous Aβ1-42 production, cytotoxicity, and β-secretase (BACE1) activity. Comparative analysis of structurally related analogues enabled the identification of molecular features associated with Aβ-lowering activity, establishing a qualitative structure–activity relationship. Peptide 33 ( P33 ) emerged as a lead candidate, selectively reducing BACE1 activity without significantly inhibiting the homologous enzyme, BACE2. In vitro blood-brain barrier (BBB) assays revealed that P33 exhibits favorable transendothelial permeability. Intraperitoneal administration of P33 in APP/PS1 mice decreased Aβ levels, reduced amyloid plaque burden, and improved performance in a behavioral recognition task without inducing cytotoxicity or systemic toxicity. These results define cis-γ-amino-L-proline peptides as a bioorganically distinct and modular scaffold for the development of intracellular modulators of Aβ production. Highlights: γLJAminoLJLLJproline peptides as metabolically stable modulators of Aβ production. P33 showed BBB permeability and BACE1 inhibition in primary cortical neurons. In APP/PS1 mice, P33 lowers amyloid burden and improves cognition. P33 shows good biocompatibility, supporting its therapeutic potential in AD